Cellular Biomedicine Group Inc (NASDAQ:CBMG) has been given a consensus broker rating score of 2.00 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has given a strong buy rating to the company.
Brokers have set a twelve-month consensus price target of $32.00 for the company and are predicting that the company will post ($0.52) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Cellular Biomedicine Group an industry rank of 163 out of 255 based on the ratings given to related companies.
Get Cellular Biomedicine Group alerts:A number of brokerages have recently issued reports on CBMG. Zacks Investment Research upgraded shares of Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a research report on Wednesday, June 27th. BidaskClub downgraded shares of Cellular Biomedicine Group from a “buy” rating to a “hold” rating in a research report on Wednesday, May 9th. ValuEngine upgraded shares of Cellular Biomedicine Group from a “sell” rating to a “hold” rating in a research report on Wednesday, April 4th. Maxim Group restated a “hold” rating on shares of Cellular Biomedicine Group in a research report on Tuesday, March 6th. Finally, B. Riley restated a “buy” rating on shares of Cellular Biomedicine Group in a research report on Friday, March 16th.
Top 5 High Tech Stocks To Watch Right Now: Masimo Corporation(MASI)
Advisors' Opinion:- [By Keith Speights]
By the end of July, Masimo Corporation (NASDAQ:MASI) appeared to be on track for even better gains than the stock's impressive 26% jump last year. The company, which makes non-invasive monitoring technologies, reported great first-quarter results in May. Masimo's launches of new products promised the potential of even better days ahead.
- [By Logan Wallace]
HL Financial Services LLC raised its holdings in shares of Masimo (NASDAQ:MASI) by 9.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 37,977 shares of the medical equipment provider’s stock after purchasing an additional 3,260 shares during the quarter. HL Financial Services LLC’s holdings in Masimo were worth $3,340,000 at the end of the most recent reporting period.
- [By VantagePoint]
Masimo Corporation (NASDAQ: MASI) had a predictive moving average crossover to the upside in early-April indicating a bullish trend. As soon as the blue line crossed above the black line, VantagePoint users knew they should start taking long positions in this market. The Neural Index also supported that move to the upside. In 18 trading days, $MASI was up almost 14 percent or $11.77 per share.
- [By Shane Hupp]
Masimo Co. (NASDAQ:MASI) CEO Joe E. Kiani sold 239,926 shares of the business’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $117.95, for a total value of $28,299,271.70. Following the completion of the transaction, the chief executive officer now directly owns 236,061 shares of the company’s stock, valued at $27,843,394.95. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
- [By Max Byerly]
Masimo Co. (NASDAQ:MASI) shares reached a new 52-week high on Tuesday . The stock traded as high as $124.38 and last traded at $123.94, with a volume of 12094 shares traded. The stock had previously closed at $123.90.
Top 5 High Tech Stocks To Watch Right Now: ESSA Pharma Inc.(EPIX)
Advisors' Opinion:- [By Ethan Ryder]
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin]
Losers Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering. InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday. Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81. Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections. Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results. LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss. Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit. Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings. Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss. Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight. Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings. The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results. Arcadia Biosciences, Inc. (N - [By Stephan Byrd]
Avid Bioservices (NASDAQ:CDMO) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.
- [By Max Byerly]
Get a free copy of the Zacks research report on ESSA Pharma (EPIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 5 High Tech Stocks To Watch Right Now: Sutor Technology Group Limited(TOR)
Advisors' Opinion:- [By Logan Wallace]
Torcoin (TOR) is a PoW/PoS coin that uses the X11 hashing algorithm. Its launch date was July 4th, 2014. Torcoin’s total supply is 1,316,179 coins and its circulating supply is 316,179 coins. The official website for Torcoin is torcoin.org. Torcoin’s official Twitter account is @thetorcoin.
- [By Logan Wallace]
Torcoin (CURRENCY:TOR) traded flat against the dollar during the one day period ending at 15:00 PM E.T. on September 15th. During the last seven days, Torcoin has traded flat against the dollar. Torcoin has a market cap of $23,561.00 and approximately $0.00 worth of Torcoin was traded on exchanges in the last 24 hours. One Torcoin coin can currently be purchased for about $0.0745 or 0.00000789 BTC on popular cryptocurrency exchanges.
Top 5 High Tech Stocks To Watch Right Now: PIMCO 25+ Year Zero Coupon US Trs ETF (ZROZ)
Advisors' Opinion:- [By ]
My preferred fund here is Vanguard Extended Duration Treasury ETF (NYSE: EDV), which owns a basket of long-term, zero-coupon bonds. It's better-known, larger, and, most important, cheaper than its competitor PIMCO 25+ Year Zero Coupon U.S. Treasury Index Exchange-Traded Fund (NYSE: ZROZ). Both are poised to rally if deflation hits and the stock market falls. But EDV is cheaper, at only 0.07% expense ratio, compared with ZROZ's 0.15%, and so it's the one that makes the cut.
Top 5 High Tech Stocks To Watch Right Now: iShares MSCI Europe Financials Sector Index Fund(EUFN)
Advisors' Opinion:- [By Todd Shriber, ETF Professor]
The iShares MSCI Europe Financials ETF (NASDAQ: EUFN) is down just over 1 percent year-to-date. While it's not alarming decline by any mean, it's a broad view: a more focused look at EUFN reveals the exchange traded fund resides about 11 percent below the 52-week high it set in February.
No comments:
Post a Comment